Life's simple measures: unlocking the proteome.

Using modified nucleotides and selecting for slow off-rates in the SELEX procedure, we have evolved a special class of aptamers, called SOMAmers (slow off-rate modified aptamers), which bind tightly and specifically to proteins in body fluids. We use these in a novel assay that yields 1:1 complexes of the SOMAmers with their cognate proteins in body fluids. Measuring the SOMAmer concentrations of the resultant complexes reflects the concentration of the proteins in the fluids. This is simply done by hybridization to complementary sequences on solid supports, but it can also be done by any other DNA quantification technology (including NexGen sequencing). We use measurements of over 1000 proteins in under 100 μL of serum or plasma to answer important medical questions, two of which are reviewed here. A number of bioinformatics methods have guided our discoveries, including principal component analysis. We use various methods to evaluate sample handling procedures in our clinical samples and can identify many parameters that corrupt proteomics analysis.

[1]  Tracy R. Keeney,et al.  From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.

[2]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[3]  Stephen A. Williams,et al.  Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.

[4]  Rachel Ostroff,et al.  The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. , 2010, Journal of proteomics.

[5]  M. Okada,et al.  Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. , 2005, The Journal of thoracic and cardiovascular surgery.

[6]  Dan Schneider,et al.  Expanding the chemistry of DNA for in vitro selection. , 2010, Journal of the American Chemical Society.

[7]  Larry Gold,et al.  High-content affinity-based proteomics: unlocking protein biomarker discovery , 2010, Expert review of molecular diagnostics.

[8]  Stephen Quake,et al.  Enhanced signals and fast nucleic acid hybridization by microfluidic chaotic mixing. , 2006, Angewandte Chemie.

[9]  Rachel Ostroff,et al.  Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics. , 2013, Advances in experimental medicine and biology.

[10]  B. Stewart,et al.  World Cancer Report , 2003 .

[11]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[12]  Alex Stewart,et al.  Automation of the SomaLogic Proteomics Assay: A Platform for Biomarker Discovery , 2009 .

[13]  H. Pass,et al.  Current status of screening for malignant pleural mesothelioma. , 2009, Seminars in thoracic and cardiovascular surgery.

[14]  R. Wehrens Chemometrics with R , 2020, Use R!.

[15]  L. Dwyer-Nield,et al.  A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. , 2008, Cancer research.

[16]  John D. Storey A direct approach to false discovery rates , 2002 .

[17]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[18]  L. Gold,et al.  Oligonucleotides as Research, Diagnostic, and Therapeutic Agents(*) , 1995, The Journal of Biological Chemistry.

[19]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[20]  Sheri K. Wilcox,et al.  Protein Signature of Lung Cancer Tissues , 2012, PloS one.

[21]  Marc Madou,et al.  Microfluidic device for rapid (<15 min) automated microarray hybridization. , 2005, Clinical chemistry.

[22]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.